Highlights

  • 4DMedical shares rose 10.48% to AUD 3.69 on 29 May 2026, extending one-year gains to 954%.
  • The company secured a commercial agreement with SimonMed Imaging, which operates more than 170 imaging centres across the United States.
  • CT:VQ and LDAf will be deployed immediately under a three-year commercial arrangement.
  • SimonMed operates across 10 US states and is supported by more than 300 radiologists.
  • The agreement includes collaboration on reimbursement evidence and Insurance Claims data to support payor engagement.
  • 4DMedical said the Partnership strengthens its position in next-generation CT-based functional imaging.

4DMedical Ltd (ASX:4DX) shares moved higher during the morning session on 29 May 2026 after the medical imaging company announced a commercial agreement with major US outpatient imaging provider SimonMed Imaging. Investors appeared to respond favourably to the update, with the stock gaining 10.48% to AUD 3.69 following the announcement.

The latest move adds to the company’s substantial share price appreciation over the past 12 months, with 4DMedical shares rising more than 954% over the year as the company continued expanding the commercial footprint of its respiratory imaging technologies across the United States healthcare market.

The newly announced agreement marks another step in the company’s US commercial rollout strategy following FDA clearance of its CT:VQ technology. Importantly, the deployment will begin immediately on commercial terms rather than through a preliminary evaluation phase, which the company described as an indication of increasing confidence in the clinical and operational value of its imaging platform.

What Does 4DMedical Do?

4DMedical is an Australian medical technology company focused on respiratory imaging and lung disease assessment. The company develops imaging software and artificial intelligence-driven solutions designed to help clinicians identify, diagnose and monitor respiratory conditions with greater precision.

Its proprietary XV Technology® converts standard imaging scans into functional lung analysis tools, allowing physicians to obtain additional insights into lung performance and cardiopulmonary function.

The company’s software portfolio includes XV Lung Ventilation Analysis Software (XV LVAS®), CT LVAS and CT:VQ, which combines ventilation and perfusion analysis capabilities for cardiothoracic imaging.

4DMedical delivers its products through a Software-as-a-Service (SaaS) model, enabling healthcare providers to integrate the technology within existing imaging infrastructure and workflows. The company also strengthened its artificial intelligence capabilities through the Acquisition of Imbio in 2023.

SimonMed Partnership Opens Access to Large US Outpatient Network

The agreement with SimonMed Imaging significantly expands 4DMedical’s reach into the US outpatient imaging market.

SimonMed, headquartered in Scottsdale, Arizona, operates more than 170 imaging centres across 10 states and is supported by a network of over 300 radiologists. Founded in 2003, the organisation has become one of the largest physician-led outpatient imaging providers in the United States.

Under the three-year agreement, SimonMed will integrate 4DMedical’s CT:VQ and LDAf technologies into its imaging services to support pulmonary assessment and quantitative cardiopulmonary analysis.

The deployment is expected to complement existing CT imaging services and provide referring clinicians with additional objective insights into regional lung function. According to the company, the integration aims to assist clinical decision-making, diagnosis, treatment planning and ongoing patient management.

The agreement also leverages 4DMedical’s SaaS-based delivery model, which supports deployment across large-scale multi-site imaging networks.

While the company noted that the contract is not immediately financially material, management described it as a favourable long-term commercial opportunity because of the scale and influence of SimonMed’s network within the US imaging market.

Commercial Deployment Begins Immediately

One of the notable aspects of the agreement is that deployment will commence immediately on commercial terms from day one.

According to 4DMedical, the arrangement does not include an evaluation or pilot phase, which management believes reflects increasing market confidence in the technology.

The deal structure includes pricing based on per-scan rates over the three-year contract period.

In addition to technology deployment, the partnership will also involve collaboration on reimbursement evidence development for CT:VQ. SimonMed will share insurance and claims data across its network, supporting engagement with public and private payors.

Reimbursement visibility is considered an important Factor for healthcare technology adoption in the United States, particularly for imaging solutions seeking wider commercial uptake.

The company indicated that the agreement could support future reimbursement discussions while helping demonstrate the clinical and operational value of CT:VQ within large imaging networks.

Management Highlights Expansion Momentum

4DMedical founder and Managing Director Andreas Fouras described the agreement as an important milestone for the company’s US growth strategy.

Management stated that the adoption by SimonMed represented validation of both the technology and its clinical application, particularly given SimonMed’s position as a large outpatient imaging provider.

The company also highlighted that CT:VQ has already been introduced into leading academic medical centres following FDA clearance, with the SimonMed agreement extending the technology into scaled commercial deployment across a broader outpatient network.

According to management commentary, the technology enables healthcare providers to derive additional cardiopulmonary information from standard CT scans without requiring additional contrast agents or nuclear medicine studies.

The company believes this capability can enhance the value extracted from existing imaging workflows while supporting more personalised patient care.

4DMedical further noted that the agreement strengthens its position within the US market as adoption of quantitative functional imaging technologies continues to expand.

SimonMed Sees Potential for Earlier Disease Detection

SimonMed’s Chief Medical Officer and Chief Innovation Officer, Dr Sean Raj, said the technology could help transform conventional imaging into a more quantitative and clinically actionable tool.

According to SimonMed, the ability to extract functional cardiopulmonary insights directly from standard CT scans may assist physicians in identifying respiratory diseases earlier and support more precise risk stratification.

The imaging provider specifically referenced conditions such as asthma and chronic obstructive pulmonary disease (COPD), which affect millions of patients globally.

SimonMed also indicated that the technology may contribute to more personalised treatment approaches and potentially improved patient outcomes through enhanced imaging insights.

The comments suggest growing interest among imaging providers in technologies that can expand the clinical Utility of existing diagnostic imaging systems without substantially changing operational workflows.

Why the Market Reacted Positively

The share price reaction following the announcement appears linked to several factors within the update.

First, the agreement expands 4DMedical’s presence into one of the largest outpatient imaging networks in the United States, increasing the visibility of its technology across a large-scale commercial healthcare platform.

Second, immediate deployment on commercial terms may have been interpreted positively by investors because it removes the need for an extended evaluation phase.

Third, the collaboration around reimbursement evidence and insurance claims data could support future commercial adoption and broader market penetration of CT:VQ.

The announcement also reinforced the company’s ongoing momentum in the US market following FDA clearance of its technology platform.

With more than 170 imaging centres included in the SimonMed network, the agreement represents another step in scaling the company’s commercial footprint beyond academic medical centres into higher-Volume outpatient imaging settings.

Focus Remains on US Commercial Expansion

The United States remains a major focus market for 4DMedical as it seeks broader adoption of its respiratory imaging technologies.

The company has continued positioning CT:VQ as a next-generation imaging solution capable of combining ventilation and perfusion analysis from standard CT scans.

As healthcare systems increasingly focus on precision diagnostics and earlier disease identification, technologies that integrate into existing imaging infrastructure may attract greater clinical and commercial interest.

4DMedical’s SaaS-based deployment model may also support scalability across hospital systems and outpatient imaging providers without requiring extensive hardware replacement.

The SimonMed agreement adds another commercial reference point for the company as it continues expanding relationships across the US healthcare and imaging sector.

What This Means for Investors

4DMedical’s latest announcement highlights continued progress in the commercial rollout of its respiratory imaging technology across the United States.

While the company noted that the SimonMed agreement is not immediately financially material, investors appeared encouraged by the scale of the imaging network, the immediate commercial deployment structure and the reimbursement collaboration component.

The update also reinforces the company’s broader strategy of expanding CT:VQ adoption across both academic medical centres and outpatient imaging networks.

With shares already up more than 954% over the past year, the market appears closely focused on the company’s ability to continue translating clinical adoption into broader commercial deployment opportunities.